Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
Tag Archives: Revlimid
James R. Berenson, MD

President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
- Love Is All You Need – Movie Premiere Benefiting the Institute for Myeloma & Bone Cancer Research March 28, 2013
- Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma February 19, 2013
- CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma November 19, 2012
- Myeloma Cure Panel Broadcast – Dr. James Berenson will discuss Multiple Myeloma disease control Without Transplant November 9, 2012
- Updates in the Treatment of Multiple Myeloma October 26, 2012
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients February 16, 2011
- Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma February 19, 2013
- CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma November 19, 2012
- Myeloma Cure Panel Broadcast – Dr. James Berenson will discuss Multiple Myeloma disease control Without Transplant November 9, 2012
- Updates in the Treatment of Multiple Myeloma October 26, 2012






May 28, 2012
0 Comments